---
schema_version: "secwatch.filing_event.v1"
accession: "0001792044-25-000004"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:23:41.338310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viatris reports FY2024 revenue $14.7B, GAAP net loss $634M, adj EPS $2.65; guides 2025 share buybacks $500-650M

## Summary
- FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.
- Free cash flow $2.0B (incl. ~$650M transaction costs) exceeded guidance; repaid $3.7B debt; leverage 2.9x.
- New product revenues $582M; 2025 expects six Phase 3 readouts for selatogrel, cenerimod, sotagliflozin.
- 2025 guidance includes Indore facility warning letter/import alert impact; enterprise cost review initiated.
- Plans $500M-$650M share repurchases in 2025; returned $825M to shareholders in 2024.

## SEC filing metadata
- accession: 0001792044-25-000004
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000179204425000004/0001792044-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000179204425000004/vtrs-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001792044-25-000004
- JSON: https://secwatch.observer/filing/0001792044-25-000004.json
- Plain text: https://secwatch.observer/filing/0001792044-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.